Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). TALZENNA is first and only PARP inhibitor approved for use with an existing standard of care (XTANDI) for adult patients with both BRCA mutated and non-BRCA HRR gene-mutated mCRPC.

Canhelp Genomics Partners with Eurobio Scientific to Expand European Markets Canhelp Genomics announced the signing of a strategic partnership agreement with Eurobio Scientific, a leading European in vitr..

Original from: Natera Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnolog..

Original from: Tempus Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has gr..

Original from: Agilent Second-quarter fiscal year 2026 - Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core compared with t..

Original from: Abbott - First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels t..

Original from: Roche - Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) management - The Liver Disease Panel includes Live..

Original from: TOBY TOBY, Inc., a biotechnology company developing non-invasive disease detection technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough D..

4.2 Direction of Technical Development of Blood Typing Reagents 4.2.1 Current Status of Technical Development of Blood Typing Reagents In recent years, in vitro diagnostic (henceforth referred to a..

Siemens Healthineers Diagnostics Signs Education Funding Agreement with Shanghai Jiao Tong University School of Medicine On May 20, the signing ceremony for the “Siemens Healthineers Diag..

Original from: GCC Business News PureLab, part of PureHealth, has signed a Memorandum of Understanding (MoU) with Baynounah Gene Solutions to explore opportunities for collaboration across diagnostics in..

Original from: Seegene Seegene, a global molecular diagnostics company, announced the European launch of its new antimicrobial resistance (AMR) testing product, Allplex™ MDRO Assay, which is CE mar..

Original from: Diasorin Diasorin (FTSE MIB: DIA) announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the LIAISON PLEX Gastrointestinal Flex Assay, a f..

Original from: Guardant Health Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liq..

Original from: QIAGEN QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and it..